HaleonMEX:HLNN 74 FCF Yield % is 7.55 as of Jun. 24, 2026, which is 31% above its 10-year median of 5.76. GuruFocus rates MEX:HLNN with a GF Score™ of 74/100 and a GF Value™ of MXN107.88. The stock has 3 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Haleon ranks better than 82.19% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Haleon's Trailing 12-Month Free Cash Flow is MXN55,180 Mil, and Market Cap is MXN676,718 Mil. Therefore, Haleon's FCF Yield % for today is 7.55%.
The historical rank and industry rank for Haleon's FCF Yield % or its related term are showing as below:
MEX:HLNN'
s FCF Yield % Range Over the Past 10 Years
Min: 3.5 Med: 5.76 Max: 7.55
Current: 7.55
During the past 7 years, the highest FCF Yield % of Haleon was 7.55%. The lowest was 3.50%. And the median was 5.76%.
MEX:HLNN's FCF Yield % is ranked better than 82.19% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.69
vs MEX:HLNN: 7.55
Haleon's FCF Margin % for the quarter that ended in Dec. 2025 was 23.84%.
Haleon FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Haleon FCF Yield % Related Terms
Haleon FCF Yield % Historical Data
* Premium members only.
The historical data trend for Haleon's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:HLNN vs ZTS, UTHR, VTRS: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleon FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haleon's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Haleon's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleon (MEX:HLNN) has a FCF Yield % of 7.55 as of Jun. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Haleon and its competitors. This is 31% above median its historical median of 5.76. Over the past decade, Haleon's FCF Yield % has ranged from 3.50 to 7.55. According to the industry distribution chart, Haleon ranks #179 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 17.8%.
Is Haleon's FCF Yield % too high?
Haleon's current FCF Yield % of 7.55 is 31% above median its 10-year median of 5.76. Over the past 10 years, this metric has ranged from a low of 3.50 to a high of 7.55. The Drug Manufacturers industry median FCF Yield % is 0.69. Haleon's value of 7.55 is 994.2% above this industry median. Based on the distribution chart, Haleon ranks #179 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haleon has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Haleon's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Haleon ranks #179 out of 1005 companies for FCF Yield %. This places Haleon in the top 18% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.69. Haleon's value of 7.55 is 994.2% above this benchmark. Historically, Haleon's own FCF Yield % has ranged from 3.50 to 7.55 over the past decade. While the company's 10-year median is 5.76 vs. the industry median of 0.69, Haleon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.69, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleon's current FCF Yield % of 7.55 is 994.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Haleon and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleon's current FCF Yield % is 7.55, which is 31% above median its own 10-year median of 5.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Haleon (MEX:HLNN) has a current FCF Yield % of 7.55. The stock's GF Value™ is MXN107.88, compared to a current price of MXN99.17 — trading 8.1% below its estimated fair value. The current FCF Yield % is 7.55, which is 31% above median its 10-year median of 5.76 and 994.2% above the Drug Manufacturers industry median of 0.69. Haleon's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Haleon (MEX:HLNN), the current FCF Yield % is 7.55 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleon (MEX:HLNN) Overvalued in 2026?
Based on GuruFocus' analysis, Haleon stock appears to be undervalued.
The current stock price of MXN99.17 is trading 8.1% below its estimated GF Value™ of MXN107.88.
Key valuation signals for MEX:HLNN:
FCF Yield %: 7.55 (31% above median its 10-year median of 5.76)
GF Value™: MXN107.88 vs. price of MXN99.17 (8.1% below fair value)
Industry Position: 994.2% above the Drug Manufacturers median (#179 of 1005)
No single metric tells the full story. See the MEX:HLNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
74GF Score
Get the complete analysis for MEX:HLNN
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:HLNN has been successfully added to your 
